A Prospecitve Multicenter, Observational Registry Study

Recruiting now

Conditions studied: Chronic Kidney Disease

In brief

This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.

Key facts

Study ID

NCT07481526

Run by

AstraZeneca

People needed

3000

Starts

2026-02-27

Expected to finish

2028-12-30

Last updated by the study team

2026-07-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients aged ≥18 years.
• Willing and able to provide written informed consent to participate in the study.
• Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
• eGFR <60 mL/min/1.73 m² for ≥3 months, OR
• Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months

You may not qualify if…

• Having a life-threatening comorbidity with life expectancy < 2 years.
• Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
• Pregnant or breastfeeding women.
• Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
• Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.

Where it is running

• Zhongshan Hospital Affilicated with Fudan University — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.